|
C14ORF145 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.95609999706659E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.01730000000722E-05 |
| Normal-vs-Stage2 |
3.8469999996682E-07 |
| Normal-vs-Stage3 |
3.45649997512965E-09 |
| Normal-vs-Stage4 |
1.89750000045841E-07 |
| Stage1-vs-Stage2 |
2.159700E-02 |
| Stage1-vs-Stage3 |
2.117100E-03 |
| Stage1-vs-Stage4 |
9.299900E-03 |
| Stage2-vs-Stage3 |
9.727200E-01 |
| Stage2-vs-Stage4 |
8.152600E-01 |
| Stage3-vs-Stage4 |
7.635800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
9.46520000155715E-08 |
| Normal-vs-AfricanAmerican |
8.458700E-03 |
| Normal-vs-Asian |
5.028100E-04 |
| Caucasian-vs-AfricanAmerican |
5.791600E-01 |
| Caucasian-vs-Asian |
5.770200E-01 |
| AfricanAmerican-vs-Asian |
9.038000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.61879999802406E-08 |
| Normal-vs-Female |
4.66649999975033E-07 |
| Male-vs-Female |
2.906800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.753200E-04 |
| Normal-vs-Age(41-60Yrs) |
1.19430000333764E-08 |
| Normal-vs-Age(61-80Yrs) |
9.84079995269838E-09 |
| Normal-vs-Age(81-100Yrs) |
4.920900E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.035600E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.383600E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.363200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.039400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.410400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.747200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.802200E-03 |
| Classical-VS-Follicular |
2.447200E-01 |
| Classical-VS-Other |
5.340200E-01 |
| Classical-VS-Normal |
2.88869999998109E-06 |
| Tall-VS-Follicular |
3.436100E-02 |
| Tall-VS-Other |
3.272400E-01 |
| Tall-VS-Normal |
7.29050000369824E-08 |
| Follicular-VS-Other |
8.323200E-01 |
| Follicular-VS-Normal |
1.53707999999142E-05 |
| Other-VS-Normal |
1.971940E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.2632999996961E-07 |
| Normal-vs-N1 |
1.50850000002478E-06 |
| N0-vs-N1 |
4.413000E-01 |
|
|
